Filing Details
- Accession Number:
- 0001209191-14-061653
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-10-03 17:11:02
- Reporting Period:
- 2014-10-01
- Filing Date:
- 2014-10-03
- Accepted Time:
- 2014-10-03 16:11:02
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557290 | A Stuart Arbuckle | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp\Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2014-10-01 | 1,607 | $106.32 | 53,074 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-10-01 | 5,373 | $107.32 | 47,701 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-10-01 | 4,037 | $108.08 | 43,664 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-10-01 | 900 | $109.19 | 42,764 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-10-01 | 400 | $110.37 | 42,364 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-10-01 | 100 | $111.52 | 42,264 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 140 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $106.32 (range $105.80 to $106.68).
- Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $107.32 (range $106.71 to $107.70).
- Open market sales reported on this line occurred at a weighted average price of $108.08 (range $107.71 to $108.60).
- Open market sales reported on this line occurred at a weighted average price of $109.19 (range $108.73 to $109.64).
- Open market sales reported on this line occurred at a weighted average price of $110.37 (range $110.09 to $110.66).
Billionaire Hedge Funds
